APP and Alzheimer disease: To confirm the in vivo efficacy of YIAD002 against Aβ, we tested if administration of YIAD002 could improve cognitive functions and reduce Aβ burden in another AD mouse model, the APP/PS1 transgenic mouse (Fig. 3E).